14 employees
Imophoron is the developer of a novel next-generation rapid-response vaccine platform, ADDomer(TM).
2017
$5.4M
from 1 investors over 1 rounds
Imophoron Ltd raised $5.4M on October 7, 2021
Investors: Octopus Ventures